Higher potency statins and the risk of new diabetes: Multicentre, observational study of administrative databases

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Dormuth, Colin R ^a   Filion, Kristian B ^b   Paterson, J Michael ^c   James, Matthew T ^d   Teare, Gary F ^e   Raymond, Colette B ^f   Rahme, Elham ^g   Tamim, Hala ^h   Lipscombe, Lorraine ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d UNIVERSITY OF CALGARY   (Canada)

^e Health Quality Council   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g MCGILL UNIVERSITY   (Canada)

^h YORK UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ORAL ANTIDIABETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG POTENCY; DRUG USE; EFFECT SIZE; FACTUAL DATABASE; FEMALE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADULT; AGED; CANADA; COHORT STUDIES; DIABETES MELLITUS; FEMALE; GREAT BRITAIN; HOSPITALIZATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RISK FACTORS; UNITED STATES;

EID: 84901704225     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3244     Document Type: Article

References (30)

1. Food and Drug Administration. FDA drug safety communication: Important safety label changes to cholesterol-lowering statin drugs. 2012. www.fda.gov/drugs/drugsafety/ucm293101.htm.
2. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924-9.
3. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
4. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, et al. Risk of diabetes with intensive-dose compared with moderate-dose statin therapy. JAMA 2011;305:2556-64.
5. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
6. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med 2010;170:1024-31.
7. Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas J-P, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011;(1):CD004816. doi:10.1002/14651858.CD004816.pub3.
8. Suissa S, Henry D, Caetano P, Dormuth CR, Ernst P, Hemmelgarn B, et al. CNODES: the Canadian Network for Observational Drug Effect Studies. Open Med 2012;6:e134-40.
9. Dormuth CR, Hemmelgarn BR, Paterson JM, James MT, Teare GF, Raymond CB, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013;346:f880.
10. Filion KB, Chateau D, Targownik LE, Gershon A, Durand M, Tamim H, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut 2014;63:552-8.
11. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005;5:5.
12. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
13. Kheterpal S, Tremper KK, Englesbe MJ, O'Reilly M, Shanks AM, Fetterman DM, et al. Predictors of postoperative acute renal failure after noncardiac surgery in patients with previously normal renal function. Anesthesiology 2007;107:892-902. (Pubitemid 350175671)
14. Ouattara A, Benhaoua H, Le Manach Y, Mabrouk-Zerguini N, Itani O, Osman A, et al. Perioperative statin therapy is associated with a significant and dose-dependent reduction of adverse cardiovascular outcomes after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2009;23:633-8.
15. Molnar AO, Coca SG, Devereaux PJ, Jain AK, Kitchlu A, Luo J, et al. Statin use associates with a lower incidence of acute kidney injury after major elective surgery. J Am Soc Nephrol 2011;22:939-46.
16. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care 2002;25:512-6. (Pubitemid 41103345)
17. High-dimensional propensity score (hd-PS), Version 1. 2013. www.hdpharmacoepi.org/download/.
18. Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512-22.
19. Pedersen T, Faergeman O, Kastelein J, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 2005;294:2437-45. (Pubitemid 41627921)
20. LaRosa J, Grundy S, Waters D, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary heart disease. N Engl J Med 2005;352:1425-35. (Pubitemid 40471450)
21. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomized trial. Lancet 2010;376:1658-69.
22. Therapeutics Initiative. High dose versus standard dose statins in stable coronary heart disease. Therapeutics Letter 2012.
23. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of diabetes among patients treated with statins: population based study. BMJ 2013;346:f2610.
24. Ko DT, Wijeysundera HC, Jackevicius CA, Yousef A, Wang J, Tu JV. Diabetes mellitus and cardiovascular events in older patients with myocardial infarction prescribed intensive-dose and moderate-dose statins. Circ Cardiovasc Qual Outcomes 2013;6:315-22.
25. Chen CW, Chen TC, Huang KY, Chou P, Chen PF, Lee CC. Differential impact of statin on new-onset diabetes in different age groups: a population-based case-control study in women from an Asian country. PLoS One 2013;8:e71817.
26. Currie O, Mangin D, Williman J, McKinnon-Gee B, Bridgford P. The comparative risk of new-onset diabetes after prescription of drugs for cardiovascular risk prevention in primary care: a national cohort study. BMJ Open 2013;3:e003475.
27. Bell DS, Dinicolantonio JJ, O'Keefe JH. Is statin-induced diabetes clinically relevant? A comprehensive review of the literature. Diabetes Obes Metab 2013. doi:10.1111/dom. 12254.
28. Wang KL, Liu CJ, Chao TF, Chen SJ, Wu CH, Huang CM, et al. Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. Am J Cardiol 2014;113:631-6.
29. Navarese EP, Szczesniak A, Kolodziejczak M, Gorny B, Kubica J, Suryapranata H. Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy? Am J Cardiovasc Drugs 2014;14:79-87.
30. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;167:492-9.